GlassScriptPhysician profile
Bryant Nam Vo
NPI 1073374542
$3,369.20
in general payments reported to CMS, 2019-2025
33 companies · $2,553 in 2025
The $2,553 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $816 · 2025: $2,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,369.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $474.78 | 2024-2025 | |
| Aop Health US, LLC | $270.40 | 2025 | Rapiblyk |
| Pfizer INC. | $261.91 | 2024-2025 | |
| Esperion Therapeutics, INC. | $233.44 | 2024-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.38 | 2024-2025 | Jardiance |
| Amgen INC. | $182.16 | 2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $159.32 | 2024-2025 | Andexxa, Farxiga, Wainua |
| Phathom Pharmaceuticals, INC. | $150.01 | 2025 | Voquezna |
| Novo Nordisk INC | $145.10 | 2024-2025 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $130.30 | 2025 | Livdelzi |
| Aimmune Therapeutics, INC. | $124.56 | 2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $108.19 | 2024-2025 | Eliquis |
| Bridgebio Pharma, INC. | $106.06 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $88.43 | 2025 | Sapien 3 Ultra Resilia |
| Alnylam Pharmaceuticals INC. | $74.71 | 2024-2025 | Amvuttra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $70.29 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.30 | 2024-2025 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $65.53 | 2025 | Evkeeza |
| Janssen Pharmaceuticals, INC | $63.87 | 2024 | Xarelto |
| Abiomed | $49.23 | 2024-2025 | Impella |
| Inspire Medical Systems, INC. | $38.38 | 2024 | Inspire |
| Azurity Pharmaceuticals, INC. | $38.20 | 2025 | Edarbi |
| Merck Sharp & Dohme LLC | $32.60 | 2025 | Verquvo |
| Glaxosmithkline, LLC. | $32.08 | 2025 | Shingrix, Arexvy |
| Daiichi Sankyo INC. | $27.41 | 2024-2025 | Injectafer |
| Scpharmaceuticals INC. | $24.67 | 2025 | |
| Mannkind Corporation | $24.64 | 2025 | |
| Microtransponder, INC. | $22.79 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $22.34 | 2024 | Arcalyst |
| Sight Sciences, INC. | $21.85 | 2025 | Tearcare System |
| Novartis Pharmaceuticals Corporation | $21.72 | 2024 | |
| Chiesi USA, INC. | $19.27 | 2025 | Juxtapid |
| Lilly USA, LLC | $18.28 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryant Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.